Abbott said it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026, after receiving all regulatory clearances necessary. The transaction enables Abbott to enter the cancer screening and diagnostics segments.
The company first announced the $23 billion deal in November.
"Proactively shaping the portfolio to anticipate future medical needs while building long-term shareholder value remains at the core of our strategic framework," said Abbott CEO Robert B. Ford in a statement. "The addition of Exact Sciences enhances Abbott's growth profile and strengthens our leadership in diagnostics. This transaction brings a powerful new platform in cancer screening and diagnostics into Abbott, advancing our mission to make care more accessible and give people more control over their health."
Exact Sciences' product offerings include the Cologuard test, a non-invasive colorectal cancer screening option; Oncotype DX, which informs treatment decisions for patients with early-stage breast cancer; Oncodetect, a tumor informed molecular residual disease (MRD) test to help identify cancer recurrence and guide follow-up care; and Cancerguard, a multi-cancer early detection blood test.
Exact Sciences is also advancing a leading pipeline of next-generation cancer diagnostics designed to detect cancer even earlier and enable regular monitoring to help people stay healthy and better manage disease.
